FDA Advisory Panel Finds Hologic’s Adiana(R) Permanent Contraception Approvable

Hologic, Inc. (Nasdaq: HOLX) announced that the FDA Obstetrics and Gynecology Devices Advisory Panel recommended that the pre market application for Adiana(R) Permanent Contraception for female sterilization is Approvable. The panel reached this decision by a vote of 10 to 3. The FDA is not required to accept, but traditionally follows the recommendations of its advisory panels. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 15th, 2007